Preclinical studies demonstrate that VEGF/ANG2 bispecific antibodies enhance pericyte coverage, reduce leakage, improve perfusion, alleviate hypoxia, increase intratumoral drug delivery, and promote immune cell infiltration, thereby suppressing tumor growth and metastasis. Here, VEGFA is linked to neoplasm.